Medical Oncologist
Targeted therapy duration
How Long Do You Need to Stay — on Targeted Therapy?
Most targeted therapies have no planned end date — they continue for as long as they are working and you can tolerate them. Whether stopping is ever possible is a newer question, and for most people the honest answer is that we do not yet know.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- No fixed end date — Most targeted therapies continue as long as they are working — not for a set number of months or cycles.
- Stopping is possible for some — For certain leukaemias with a deep, sustained response, stopping under monitoring is now a recognised goal.
- Treatment fatigue is real — Taking a drug every day for years has a weight to it. That weight is worth discussing with your team.
- Do not stop alone — Stopping without your oncologist's knowledge carries real risks — and the conversation is what keeps your options open.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
For most cancers, targeted therapy continues as long as it is working and you can tolerate it — there is no fixed end date. For a minority, particularly some leukaemia patients with a deep, sustained response, stopping under close monitoring is now a recognised approach. Your oncologist decides based on your response markers, not a calendar.
Why is there no fixed end date for most targeted therapies?
Targeted therapy works by blocking a specific signal or protein that your cancer cells depend on to grow.
Removing that block — by stopping the drug — would allow the cancer to use that pathway again. That is why NCCN and ESMO guidelines for most solid tumours recommend continuing targeted therapy as long as it is working and tolerated.
That can feel hard to hear. But stable disease on targeted therapy is a real, meaningful outcome — and for many people it holds for years.
Can you ever stop targeted therapy completely?
For some blood cancers, particularly certain leukaemias treated with tyrosine kinase inhibitors, stopping has become a recognised goal for a subset of patients.
ELN and ESMO guidelines describe this as treatment-free remission: stopping the drug under very close monitoring after the cancer has remained at an undetectable level for a sustained period.
For most solid tumour targeted therapies — lung, breast, bowel, kidney — stopping is not a standard goal, and the evidence is still early. We do not yet know which patients, if any, can safely stop long-term.
If this is a question on your mind, raise it with your oncologist. The answer will depend on your cancer type and your specific drug.
What if taking targeted therapy every day is exhausting you?
Treatment fatigue is real. Taking a tablet every day, managing side effects, and attending regular monitoring for months or years adds up.
If that weight is getting too much, tell your oncologist. There may be options — a dose adjustment, a switch to a better-tolerated drug in the same class, or a planned break if the evidence supports it for your drug.
Do not stop on your own. A sudden stop can allow rapid disease progression, and that narrows the choices available to you afterwards.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
How does your team decide whether stopping is possible for you?
Review your response markers
Your oncologist looks at your most recent results — scans, blood tests, or molecular markers — to see how deep and stable your response has been.
Confirm how long the response has held
Most guidelines require a response to have been sustained over a meaningful period before stopping can be considered at all.
Consider your cancer type and drug
The evidence for stopping varies widely between cancer types and drugs. Your oncologist will tell you whether it applies to your situation.
Plan monitoring if stopping is agreed
If stopping is the right step, your team will set up frequent follow-up appointments and tests so that any sign of return is caught early.
Decide together
This is a shared decision. Your priorities — managing side effects, quality of life, peace of mind — are part of the picture alongside the clinical evidence.
What else do people ask about staying on targeted therapy long-term?
Does needing to take this indefinitely mean my cancer will never go away?
Not exactly, and the framing is worth unpacking. Many targeted therapies work by controlling the cancer rather than eliminating it — the way a blood pressure tablet controls blood pressure without curing the underlying condition. Taking the drug long-term does not mean the cancer is active or growing; it often means the opposite. Ask your oncologist what your current scans and markers are actually showing, and what the treatment goal is now.
What happens if I stop taking it without telling my team?
The risk is rapid disease progression. Targeted therapies work by blocking a signal your cancer depends on, and when you remove that block abruptly, cancer cells can start using that pathway again — sometimes quickly. This is not a warning designed to frighten you; it is why planned, monitored stopping is very different from stopping alone at home. If you are struggling to take it, that conversation belongs with your team, not in a decision made on your own.
Is it safe to take targeted therapy for many years?
Long-term safety data for most targeted therapies is still being collected, and the honest answer is that we know much more than we did five years ago and less than we will know five years from now. ESMO and NCCN guidance recommends ongoing treatment while it is working, because the risks of stopping are generally better understood than the risks of very long-term use. Regular monitoring — which may include heart function scans, liver tests, or blood pressure checks depending on your drug — is how your team stays ahead of any cumulative effects.
Can I take a planned break from targeted therapy?
For some drugs and cancer types, structured treatment breaks have been studied. The evidence varies considerably, and this is an area where your oncologist's knowledge of your specific situation matters more than general guidance. The terms used in research are 'intermittent therapy' and 'drug holiday'. Ask directly whether this is something the evidence supports for your drug — your oncologist should be able to give you a clear answer, even if that answer is that we do not yet know.
What happens when the targeted therapy stops working?
When targeted therapy stops working — a process called acquired resistance — your oncologist will reassess what comes next. That often means a different drug targeting the same pathway, a different pathway altogether, or a shift to another treatment approach. This transition is planned, not a crisis: your monitoring tests are designed to catch progression early, before symptoms develop, so that the next step can be chosen carefully. The answer depends on your cancer type and what options have emerged since you started.
Did you know?
Treatment-free remission — stopping targeted therapy while the disease stays undetectable — has become a recognised clinical goal for a subset of patients with certain leukaemias, according to ELN and ESMO guidance.
It is one of the fastest-developing areas in oncology, and the criteria for who can attempt it are still being refined.
Source: European LeukemiaNet (ELN) and ESMO Clinical Practice Guidelines
Explore 39 more Monitoring, Resistance & Long-Term Response topics
Long-Term Response, Stopping & Survivorship
- Am I Still a Cancer Patient? Identity After Long-Term Response
- Bone Health, Heart Health and Late Effects to Monitor
- Can You Ever Stop Targeted Therapy If the Cancer Is Gone?
- Drug Holidays: Are Planned Breaks Safe?
- Follow-Up Schedule After Stopping Targeted Therapy
- How Long Do You Have to Stay on Targeted Therapy?
- Long-Term Effects of Taking a TKI for 5 or 10 Years
- Restarting Treatment After a Break
- Treatment-Free Remission in CML: Who Can Stop Their TKI?
- Your Survivorship Care Plan: What Should Be In It
Monitoring, Scans & Response Assessment
- Are Tumour Markers Reliable on Targeted Therapy?
- Complete Response, Partial Response, Stable Disease: What Each Means
- Do I Need Regular Brain MRIs on Targeted Therapy?
- How Doctors Measure Whether Targeted Therapy Is Working
- How Often Will I Need Scans on Targeted Therapy?
- How to Read a CT or PET Scan Report Without Panicking
- Is 'Stable Disease' Good News or Bad News?
- Scanxiety: How to Get Through the Wait for Scan Results
- Tumour Flare and Pseudoprogression: When Growth Isn't Really Growth
- Understanding PFS, OS and Median Survival Without Losing Hope
- What Happens at a Follow-Up Visit: A Walk-Through
- Which Blood Tests Are Repeated Every Month and Why
- ctDNA Monitoring: Can a Blood Test Predict Progression Early?
Resistance, Progression & Next Lines
- Being Told 'There Are No More Options': Is That Really True?
- Brain Metastases on Targeted Therapy: Does Your Drug Reach the Brain?
- Can You Continue the Same Drug After Progression?
- Combination Therapy to Overcome Resistance
- Do You Need Another Biopsy When the Cancer Progresses?
- Histologic Transformation: When Lung Cancer Changes Type
- How to Emotionally Process a Progression Scan
- Leptomeningeal Disease: Symptoms, Diagnosis and Treatment
- Life After ALK Inhibitor Resistance: Sequencing Your Options
- MET Amplification and Other Bypass Resistance Mechanisms
- Oligoprogression: When Only One or Two Spots Grow
- Primary vs Acquired Resistance: Two Very Different Problems
- Should You Change Hospitals After Progression?
- What Happens After Osimertinib Stops Working?
- What Is Sequencing and Why the Order of Drugs Matters
- Why Does Targeted Therapy Stop Working? The Biology of Resistance
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Does how long I have been on targeted therapy tell you whether it is still working?
Not on its own. Duration is not the same as response. Some people continue on targeted therapy for years with stable disease; others see progression earlier. What tells your team whether the drug is still working is your monitoring results — scans, blood tests, molecular markers — not the number of months you have been taking it. Response is measured, not assumed from time on treatment.
My oncologist said I may be on this for life. Does that mean my cancer will never go away?
Not necessarily, and the phrase 'for life' is worth discussing directly with your oncologist. Many targeted therapies aim to control the cancer rather than eliminate it — and sustained control is a real outcome, not a sign that treatment is failing. For some people, the question of whether stopping is ever possible changes as evidence accumulates. Ask what your current markers are showing and whether the treatment goal has shifted since you started.
What does treatment-free remission mean, and could it apply to me?
Treatment-free remission means stopping targeted therapy while the cancer remains at an undetectable level, under close monitoring. It is currently a recognised approach for a subset of patients with certain leukaemias who meet specific response criteria set out in ELN and ESMO guidance. For solid tumours — lung, breast, bowel — the evidence is much earlier and it is not yet a standard option. Whether it could apply to you depends on your cancer type, your drug, and how deep and sustained your response has been. Ask your oncologist directly.
Is it safe to take a targeted therapy tablet every day for years?
Long-term safety is an active area of research, and monitoring programmes for most drugs are designed specifically to watch for cumulative effects. ESMO and NCCN guidance recommends continuing while the drug is working, because the risks of stopping are generally clearer than the risks of long-term use. Regular check-ups — which vary by drug and may include heart scans, liver tests, or blood pressure checks — are how your team stays ahead of any problem that develops over time.
What if I want to stop because the side effects are too difficult?
This is a completely legitimate reason to have a conversation with your oncologist. Side effects that affect your quality of life are part of the clinical picture, not a complaint. Your team may be able to adjust your dose, switch you to a different drug in the same class, or explore whether a structured break is supported by the evidence for your particular drug. What they need is the conversation — which keeps your options open in a way that stopping alone does not.
How often will I need monitoring while on long-term targeted therapy?
Monitoring frequency depends on your cancer type, the drug you are on, and how stable your response is. Early in treatment, tests are usually more frequent. For people on long-term stable therapy, monitoring may settle into a less frequent pattern — though it never stops entirely while you are on the drug. Ask your team what the schedule is, what they are watching for, and what would trigger a change in your treatment or monitoring.